Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, describes the design of the ongoing Phase III PACIFICA trial (NCT03165734), which aims to confirm efficacy and safety of pacritinib versus best available therapy (BAT) in patients with myelofibrosis (MF) and severe thrombocytopenia. Prof. Harrison explains that recent studies have demonstrated that similarly to momelotinib, pacritinib targets ACVR1, which translates to a transfusion benefit. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.